1-[difluoro(trifluoromethoxy)methoxy]-1,2,2-trifluoroethylene

Endpoint summary

Description of key information

Because of the physico-chemical properties and conditions of use of the substance inhalation is the most likely route of exposure for human.

An acute toxicity study conducted by inhalation showed that 4 hour-exposure to MOVE 3 vapours at the concentration of 20.65 mg/L did not cause any mortality and adverse effects on rat.

No studies are available of acute toxicity by oral and dermal routes.

Key value for chemical safety assessment

Acute toxicity: via oral route

Link to relevant study records

Reference

Endpoint:

acute toxicity: oral

Data waiving:

study scientifically not necessary / other information available

Justification for data waiving:

the study does not need to be conducted because a study on acute toxicity by the inhalation route is available

other:

Reason / purpose for cross-reference:

data waiving: supporting information

Reason / purpose for cross-reference:

data waiving: supporting information

Reason / purpose for cross-reference:

data waiving: supporting information

Endpoint conclusion

Endpoint conclusion:

no study available

Quality of whole database:

no studies of acute toxicity by oral route are available.

Acute toxicity: via inhalation route

Endpoint conclusion

Endpoint conclusion:

no adverse effect observed

Dose descriptor:

discriminating conc.

Value:

20 650 mg/m³ air

Quality of whole database:

One study on the test item is available. This study was conducted according to standard OECD guideline and in compliance with GLP. The study is suitable for the assessment of acute toxicity via inhalation, the overall quality of the dataset for acute toxicity by inhaltion is therefore considered to be good.

Acute toxicity: via dermal route

Endpoint conclusion

Endpoint conclusion:

no study available

Quality of whole database:

no studies of acute toxicity by dermal route are available.

Additional information

The substance is a very volatile low boiling point liquid (BP 19.5 °C, VP =97 kPa.at 20°C), only used in industrial applications where oral exposure is not anticipated and operational and engineering controls are in place in order to control human exposure by dermal and inhalation routes. Considering the physico-chemical properties of the substance and its uses, inhalation is the most likely route of exposure therefore testing by oral and dermal route is considered not necessary.

An acute inhalation toxicity study conducted according to OECD guideline 403 and in compliance with good laboratory practices (GLP) is available.

A group of five male and five female albino rats was exposed for a single 4-hour period to a vapour of the MOVE 3 at a chemically determined mean atmosphere concentration of 20.65 ± 0.55 mg/L air. There were no deaths, no clinical signs and no macroscopic pathology findings. Body weight was not adversely affected in male animals. Minor effects on female body weight was observed but the relationship of these effects to treatment with the test item is unclear.

The median lethal concentration (LC50, 4h) of the test substance is concluded to be higher than 20.65 mg/L for male and female rats.

Justification for classification or non-classification

The median lethal concentration (LC50, 4h) of the test substance is higher than 20.65 mg/L for male and female rats, therefore the test substance does not meet the classification criteria of EC Regulation No. 1272/2008 (CLP / EU GHS).

As no mortality and significant signs of toxicty were observed up to the concentrations of 20 mg/L, the substance does not fullfill the classification criteria according to UN GHS Category 5 criteria for acute toxicity by inhalation.

Moreover, no sign of impairment was observed in any investigated organ therefore MOVE 3 does not require STOT SE classification (inhalation) according to Regulation (EC) No. 1272/2008 (CLP / EU GHS) and UN GHS criteria.